 |
|
|
| |
Efficacy and Safety of Finite 48-week Treatment With the
siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379
in HBeAg Negative Virologically Suppressed Chronic Hepatitis
B Patients: Results from the REEF-2 Study
|
| |
| |
EASL 2022 June 22-26 London
Kosh Agarwal,1 Maria Buti,2 Florian van Bömmel,3 Pietro Lampertico,4 Ewa Janczewska,5 Marc Bourliere,6
Thomas Vanwolleghem,7,8 Oliver Lenz,9 Thierry Verbinnen,9 Thomas N. Kakuda,9 Cristiana Mayer,9 John Jezorwski,9 Maria Beumont,9 Ronald Kalmeijer,9 Michael Biermer,9 Isabelle Lonjon-Domanec9
1Institute of Liver Studies, King's College Hospital, London, England; 2Hospital Universitario Valle de Hebrón, Barcelona, Spain; 3University Hospital Leipzig, Leipzig, Germany; 4Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; 5Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland; 6Hôpital Saint Joseph, Marseille, France; 7Antwerp University Hospital (UZA), Edegem, Belgium; 8Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; 9Janssen Research & Development.
|
| |
|
|
|
|
|
